(NASDAQ: GNLX) Genelux's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.53%.
Genelux's earnings in 2026 is -$31,874,000.On average, 8 Wall Street analysts forecast GNLX's earnings for 2026 to be -$38,036,550, with the lowest GNLX earnings forecast at -$44,003,068, and the highest GNLX earnings forecast at -$32,363,031. On average, 6 Wall Street analysts forecast GNLX's earnings for 2027 to be -$36,742,790, with the lowest GNLX earnings forecast at -$40,646,902, and the highest GNLX earnings forecast at -$32,363,031.
In 2028, GNLX is forecast to generate -$9,315,074 in earnings, with the lowest earnings forecast at -$42,511,439 and the highest earnings forecast at $16,780,831.